Exact Sciences Co. (NASDAQ:EXAS) Shares Bought by Kestra Private Wealth Services LLC

Kestra Private Wealth Services LLC raised its holdings in shares of Exact Sciences Co. (NASDAQ:EXAS) by 5.3% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 5,216 shares of the medical research company’s stock after acquiring an additional 264 shares during the period. Kestra Private Wealth Services LLC’s holdings in Exact Sciences were worth $386,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also bought and sold shares of the business. Eagle Wealth Strategies LLC acquired a new position in Exact Sciences during the fourth quarter valued at $296,000. Marco Investment Management LLC increased its stake in shares of Exact Sciences by 1.1% in the 4th quarter. Marco Investment Management LLC now owns 83,285 shares of the medical research company’s stock worth $6,161,000 after acquiring an additional 930 shares during the last quarter. Truist Financial Corp raised its holdings in shares of Exact Sciences by 4.9% during the 4th quarter. Truist Financial Corp now owns 19,304 shares of the medical research company’s stock worth $1,428,000 after acquiring an additional 908 shares during the period. Stanley Laman Group Ltd. purchased a new position in shares of Exact Sciences during the 4th quarter worth $8,821,000. Finally, Syon Capital LLC acquired a new position in shares of Exact Sciences during the 4th quarter valued at about $215,000. 88.82% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on EXAS shares. Citigroup reaffirmed a “buy” rating and set a $100.00 target price on shares of Exact Sciences in a research note on Wednesday, April 3rd. Canaccord Genuity Group reduced their price target on shares of Exact Sciences from $100.00 to $90.00 and set a “buy” rating on the stock in a research report on Thursday, February 22nd. William Blair reiterated an “outperform” rating on shares of Exact Sciences in a research report on Thursday, February 22nd. Finally, TheStreet downgraded Exact Sciences from a “c-” rating to a “d+” rating in a research report on Monday, February 26th. Two research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. Based on data from MarketBeat.com, Exact Sciences currently has a consensus rating of “Moderate Buy” and an average price target of $99.07.

Insiders Place Their Bets

In other news, CEO Kevin T. Conroy sold 1,155 shares of the stock in a transaction on Wednesday, May 1st. The stock was sold at an average price of $60.15, for a total value of $69,473.25. Following the sale, the chief executive officer now directly owns 1,156,191 shares in the company, valued at $69,544,888.65. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In other Exact Sciences news, CEO Kevin T. Conroy sold 1,155 shares of the company’s stock in a transaction dated Wednesday, May 1st. The stock was sold at an average price of $60.15, for a total transaction of $69,473.25. Following the sale, the chief executive officer now owns 1,156,191 shares in the company, valued at approximately $69,544,888.65. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Jacob A. Orville sold 966 shares of the stock in a transaction dated Thursday, February 15th. The shares were sold at an average price of $61.43, for a total value of $59,341.38. Following the completion of the sale, the insider now directly owns 7,488 shares in the company, valued at approximately $459,987.84. The disclosure for this sale can be found here. Insiders sold a total of 70,611 shares of company stock worth $4,255,377 over the last 90 days. Corporate insiders own 1.30% of the company’s stock.

Exact Sciences Stock Performance

NASDAQ EXAS opened at $61.41 on Wednesday. The company has a debt-to-equity ratio of 0.74, a current ratio of 2.32 and a quick ratio of 2.07. The company has a market cap of $11.29 billion, a P/E ratio of -53.87 and a beta of 1.26. The stock has a 50-day moving average of $63.58 and a two-hundred day moving average of $64.69. Exact Sciences Co. has a 1-year low of $56.05 and a 1-year high of $100.77.

Exact Sciences (NASDAQ:EXAS) last posted its quarterly earnings data on Wednesday, February 21st. The medical research company reported ($0.27) EPS for the quarter, beating the consensus estimate of ($0.53) by $0.26. The business had revenue of $646.89 million during the quarter, compared to analyst estimates of $638.83 million. Exact Sciences had a negative net margin of 8.17% and a negative return on equity of 6.60%. The business’s revenue for the quarter was up 17.0% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.72) earnings per share. As a group, analysts anticipate that Exact Sciences Co. will post -0.86 EPS for the current year.

About Exact Sciences

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.